ofloxacin has been researched along with Inflammatory Response Syndrome, Systemic in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients receiving chemotherapy for solid tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable infection, and hospitalization." | 5.11 | Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. ( Billingham, L; Bower, M; Cullen, M; Fernando, I; Gaunt, C; Gollins, S; Hastings, M; Huddart, R; Rea, D; Simmonds, P; Stanley, A; Steven, N; Stuart, N, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cullen, M | 1 |
| Steven, N | 1 |
| Billingham, L | 1 |
| Gaunt, C | 1 |
| Hastings, M | 1 |
| Simmonds, P | 1 |
| Stuart, N | 1 |
| Rea, D | 1 |
| Bower, M | 1 |
| Fernando, I | 1 |
| Huddart, R | 1 |
| Gollins, S | 1 |
| Stanley, A | 1 |
| Andrès, E | 1 |
| Gaunard, A | 1 |
| Blicklé, JF | 1 |
| Kuhnert, C | 1 |
| Goichot, B | 1 |
| Schlienger, JL | 1 |
| Brogard, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors[NCT00005590] | Phase 3 | 0 participants | Interventional | 1999-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ofloxacin and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineopl | 2005 |
1 other study available for ofloxacin and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Systemic reactions after intravesical BCG instillation for bladder cancer.
Topics: Administration, Intravesical; Aged; Anti-Infective Agents; BCG Vaccine; Humans; Male; Middle Aged; O | 2001 |